NO20006336L - Glukagon-liknende peptid-1 forbedrer <beta>-celle respons på glukose i individer med svekket glukosetoleranse - Google Patents

Glukagon-liknende peptid-1 forbedrer <beta>-celle respons på glukose i individer med svekket glukosetoleranse

Info

Publication number
NO20006336L
NO20006336L NO20006336A NO20006336A NO20006336L NO 20006336 L NO20006336 L NO 20006336L NO 20006336 A NO20006336 A NO 20006336A NO 20006336 A NO20006336 A NO 20006336A NO 20006336 L NO20006336 L NO 20006336L
Authority
NO
Norway
Prior art keywords
glucagon
peptide
individuals
enhances
beta
Prior art date
Application number
NO20006336A
Other languages
English (en)
Other versions
NO20006336D0 (no
Inventor
Burhard Goke
Maria Byrne
Thomas R Coolidge
Original Assignee
Bionebraska Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22215287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20006336(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bionebraska Inc filed Critical Bionebraska Inc
Publication of NO20006336D0 publication Critical patent/NO20006336D0/no
Publication of NO20006336L publication Critical patent/NO20006336L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Preparat for behandling av svekket glukosetoleranse (impaired glucose tolerance, IGT) inkluderende en forbindelse som binder til en resepter for glukagon-lignende peptid-l, og en farmasøytisk bærer. Mengden av forbindelsen som er tilstede er en mengde som er effektiv til å forbedre pankreatisk p- celle-sensitivitet overfor blodglukosenivåer i et menneske med IGT. Fremgangsmåte for forbedring av mønsteret av insulinsekresjonsresponser i et menneske med IGT ved administrering til mennesket omfattende en forbindelse som binder til en resepter for glukagon-lignende peptid-1 og en farmasøytisk bærer.
NO20006336A 1998-06-12 2000-12-12 Glukagon-liknende peptid-1 forbedrer <beta>-celle respons på glukose i individer med svekket glukosetoleranse NO20006336L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8904498P 1998-06-12 1998-06-12
PCT/US1999/010040 WO1999064061A1 (en) 1998-06-12 1999-05-07 GLUCAGON-LIKE PEPTIDE-1 IMPROVES β-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE

Publications (2)

Publication Number Publication Date
NO20006336D0 NO20006336D0 (no) 2000-12-12
NO20006336L true NO20006336L (no) 2001-02-12

Family

ID=22215287

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006336A NO20006336L (no) 1998-06-12 2000-12-12 Glukagon-liknende peptid-1 forbedrer <beta>-celle respons på glukose i individer med svekket glukosetoleranse

Country Status (30)

Country Link
US (1) US7265087B1 (no)
EP (2) EP1419783A3 (no)
JP (1) JP2002517469A (no)
KR (1) KR20010052800A (no)
CN (1) CN1209166C (no)
AP (1) AP2001002027A0 (no)
AT (1) ATE270897T1 (no)
AU (2) AU758825B2 (no)
BG (1) BG64975B1 (no)
BR (1) BR9911112A (no)
CA (1) CA2334872C (no)
CZ (1) CZ294848B6 (no)
DE (1) DE69918691T2 (no)
DK (1) DK1083924T3 (no)
EA (1) EA004538B1 (no)
ES (1) ES2224659T3 (no)
GE (1) GEP20033015B (no)
HU (1) HUP0102193A2 (no)
ID (1) ID28617A (no)
IL (2) IL140223A0 (no)
MX (1) MXPA00012286A (no)
NO (1) NO20006336L (no)
NZ (2) NZ508823A (no)
OA (1) OA11694A (no)
PL (1) PL195662B1 (no)
PT (1) PT1083924E (no)
SK (1) SK19042000A3 (no)
TR (1) TR200100079T2 (no)
UA (1) UA69412C2 (no)
WO (1) WO1999064061A1 (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US20020025306A1 (en) * 2000-01-07 2002-02-28 Baetge Edward E. Methods of increasing the glucose responsiveness of pancreatic ss-cells
EP2062593A3 (en) 2000-12-01 2011-08-17 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive peptide
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
AU2003220125B2 (en) 2002-03-20 2006-06-15 Mannkind Corporation Inhalation apparatus
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US8921311B2 (en) * 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
EP2322180B1 (en) 2004-08-23 2015-05-27 MannKind Corporation Diketopiperazine salts for drug delivery
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US8299025B2 (en) 2005-02-03 2012-10-30 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006126688A1 (ja) * 2005-05-27 2006-11-30 Asubio Pharma Co., Ltd. インスリン抵抗性改善剤
RU2390325C2 (ru) 2005-09-14 2010-05-27 Маннкайнд Корпорейшн Способ приготовления лекарственного препарата, основанный на увеличении сродства активных агентов к поверхностям кристаллических микрочастиц
RU2403059C2 (ru) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент
AU2007240313B2 (en) 2006-04-20 2012-02-02 Amgen Inc. GLP-1 compounds
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
WO2009046850A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Cgrp as a therapeutic agent
AU2008306218A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
US8636001B2 (en) 2008-06-13 2014-01-28 Mannkind Corporation Dry powder inhaler and system for drug delivery
DK2609954T3 (da) 2008-06-20 2022-02-14 Mannkind Corp Interaktivt apparat til realtidsafbildning af inhalationspræstationer
US20120058105A1 (en) * 2008-06-27 2012-03-08 Martin Kean Chong Ng Method of treatment of vascular complications
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid development and / or completion of substantially steady-state drug delivery
EP2582421A1 (en) 2010-06-21 2013-04-24 MannKind Corporation Dry powder drug delivery system and methods
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012135765A2 (en) 2011-04-01 2012-10-04 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG11201503526UA (en) 2012-12-21 2015-06-29 Sanofi Sa Dual glp1/gip or trigonal glp1/gip/glucagon agonists
MX2020009878A (es) 2013-07-18 2022-07-27 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos.
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
CN104267194B (zh) * 2014-09-23 2016-01-13 上海市东方医院 人胰高血糖素样肽-1、抗体及其试剂盒
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
JP7350851B2 (ja) * 2018-11-12 2023-09-26 天津薬物研究院有限公司 グルカゴン由来ペプチド及びその用途
CN113430154A (zh) * 2021-05-21 2021-09-24 深圳市前海金卓生物技术有限公司 分泌glp-1的蛋白表达系统及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100600457B1 (ko) 1996-06-05 2006-07-13 로셰 디아그노스틱스 게엠베하 엑센딘 유사체, 이의 제조방법 및 이를 함유한 약제
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6344180B1 (en) * 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes

Also Published As

Publication number Publication date
EP1083924B1 (en) 2004-07-14
IL140223A0 (en) 2002-02-10
AU3889999A (en) 1999-12-30
JP2002517469A (ja) 2002-06-18
PL345212A1 (en) 2001-12-03
BG64975B1 (bg) 2006-11-30
PL195662B1 (pl) 2007-10-31
DE69918691D1 (de) 2004-08-19
UA69412C2 (uk) 2004-09-15
GEP20033015B (en) 2003-07-25
SK19042000A3 (sk) 2001-11-06
AU2003212050A1 (en) 2003-08-14
IL140223A (en) 2010-12-30
EP1419783A2 (en) 2004-05-19
ATE270897T1 (de) 2004-07-15
CN1209166C (zh) 2005-07-06
HUP0102193A2 (hu) 2001-10-28
AP2001002027A0 (en) 2001-03-31
AU758825B2 (en) 2003-04-03
EA004538B1 (ru) 2004-06-24
CA2334872C (en) 2014-08-19
ID28617A (id) 2001-06-21
DK1083924T3 (da) 2004-11-22
PT1083924E (pt) 2004-10-29
WO1999064061A1 (en) 1999-12-16
NO20006336D0 (no) 2000-12-12
ES2224659T3 (es) 2005-03-01
US7265087B1 (en) 2007-09-04
EP1083924A1 (en) 2001-03-21
MXPA00012286A (es) 2002-10-17
BG105079A (en) 2001-09-28
EP1419783A3 (en) 2005-01-12
CA2334872A1 (en) 1999-12-16
NZ527473A (en) 2005-02-25
NZ508823A (en) 2003-10-31
AU2003212050B2 (en) 2006-02-16
OA11694A (en) 2005-01-12
BR9911112A (pt) 2001-11-27
KR20010052800A (ko) 2001-06-25
CN1311687A (zh) 2001-09-05
CZ20004614A3 (en) 2001-06-13
TR200100079T2 (tr) 2001-06-21
EA200100029A1 (ru) 2001-10-22
DE69918691T2 (de) 2005-07-21
CZ294848B6 (cs) 2005-03-16

Similar Documents

Publication Publication Date Title
NO20006336L (no) Glukagon-liknende peptid-1 forbedrer &lt;beta&gt;-celle respons på glukose i individer med svekket glukosetoleranse
Gangadharan Komala et al. Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes
MXPA02011624A (es) Uso de una composicion de celecoxib para alivio rapido del dolor.
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
DK2027870T3 (da) Kontrol af blodglucose ved diabetesbehandling under anvendelse af pulmonært indgivet insulin i kombination med basalinsulin
NO970519L (no) Behandling av type II diabetes mellitus med amylinagonister
IL144703A0 (en) Methods and reagents for treating glucose metabolic disorders
CA2187803A1 (en) Methods of treating disease using sertoli cells and allografts or xenografts
Hu et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers
Chaudhuri et al. Exenatide induces an increase in vasodilatory and a decrease in vasoconstrictive mediators
EP1733734A3 (en) Placental alkaline phosphatase to control diabetes
NO20083276L (no) Behandling av diabetes med tiazolidindion og sulfonylurea
Devineni et al. Pharmacokinetics of nateglinide in renally impaired diabetic patients
Yildirim et al. The effects of long‐term oral administration of L‐arginine on the erectile response of rabbits with alloxan‐induced diabetes
Patel et al. Saxagliptin, a potent, selective inhibitor of DPP‐4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects
Paquot et al. Hepatic insulin resistance in obese non‐diabetic subjects and in type 2 diabetic patients
Chen et al. Saxagliptin add‐on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double‐blind, placebo‐controlled trial
Garcia‐Soria et al. The dipeptidyl peptidase‐4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus
Ramesh et al. Medial preoptic alpha-2 adrenoceptors in the regulation of sleep-wakefulness
Hu et al. Single‐dose and multiple‐dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects
Zhi et al. Dose‐dependent effect of piragliatin, a glucokinase activator, on the QT interval following short‐term multiple doses in patients with type 2 diabetes mellitus
Zdravkovic et al. The effects of NN414, a SUR1/Kir6. 2 selective potassium channel opener, in healthy male subjects
AU3360000A (en) Use of 4-amino pyridine for treatment of peripheral neuropathies
Bottero et al. Atrophy of the oro-pharyngeal mucosa caused by vitamin B12 and folic acid deficiency. Etiopathologic aspects and clinico-therapeutic problems
Krut, LH, Seftel, HC & Joffe Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application